Bausch Health Companies Inc. (BHC) |
| 5.36 -0.05 (-0.92%) 05-29 16:00 |
| Open: | 5.39 |
| High: | 5.405 |
| Low: | 5.285 |
| Volume: | 2,521,224 |
| Market Cap: | 2,002(M) |
| PE Ratio: | -1.65 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 6.29 |
| Resistance 1: | 5.89 |
| Pivot price: | 5.42 |
| Support 1: | 5.24 |
| Support 2: | 4.36 |
| 52w High: | 8.69 |
| 52w Low: | 4.41 |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
| EPS | -3.240 |
| Book Value | -5.510 |
| PEG Ratio | 0.01 |
| Gross Profit | 20.028 |
| Profit Margin (%) | -11.47 |
| Operating Margin (%) | 20.64 |
| Return on Assets (ttm) | 5.9 |
| Return on Equity (ttm) | 0.0 |
Thu, 28 May 2026
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China - PR Newswire
Tue, 26 May 2026
Bausch Health (BHC) director Amy Wechsler granted $250,000 in RSUs - Stock Titan
Tue, 26 May 2026
Bausch Health (NYSE: BHC) director receives $250,000 RSU equity grant - Stock Titan
Tue, 26 May 2026
Bausch Health (BHC) director awarded $250K in RSUs - Stock Titan
Tue, 26 May 2026
Bausch Health (BHC) director awarded $250K in restricted share units - Stock Titan
Tue, 19 May 2026
Bausch Health Announces 2026 Annual Meeting of Shareholder Results - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |